Oppenheimer Asset Management Inc. Decreases Holdings in Global X Genomics & Biotechnology ETF $GNOM

Oppenheimer Asset Management Inc. trimmed its position in Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) by 75.4% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 22,041 shares of the company’s stock after selling 67,590 shares during the period. Oppenheimer Asset Management Inc.’s holdings in Global X Genomics & Biotechnology ETF were worth $856,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also made changes to their positions in GNOM. Flow Traders U.S. LLC lifted its holdings in shares of Global X Genomics & Biotechnology ETF by 52.4% during the 2nd quarter. Flow Traders U.S. LLC now owns 238,725 shares of the company’s stock valued at $2,012,000 after purchasing an additional 82,063 shares during the last quarter. Insight Advisors LLC PA grew its stake in Global X Genomics & Biotechnology ETF by 47.9% during the 2nd quarter. Insight Advisors LLC PA now owns 59,675 shares of the company’s stock worth $503,000 after buying an additional 19,319 shares during the last quarter. Sei Investments Co. increased its position in Global X Genomics & Biotechnology ETF by 110.4% during the 2nd quarter. Sei Investments Co. now owns 23,073 shares of the company’s stock valued at $194,000 after buying an additional 12,105 shares in the last quarter. Creative Financial Designs Inc. ADV raised its stake in Global X Genomics & Biotechnology ETF by 86.7% in the second quarter. Creative Financial Designs Inc. ADV now owns 22,301 shares of the company’s stock valued at $188,000 after buying an additional 10,358 shares during the last quarter. Finally, Jane Street Group LLC boosted its holdings in Global X Genomics & Biotechnology ETF by 7.7% in the first quarter. Jane Street Group LLC now owns 143,713 shares of the company’s stock worth $1,143,000 after acquiring an additional 10,308 shares in the last quarter. 56.95% of the stock is owned by institutional investors and hedge funds.

Global X Genomics & Biotechnology ETF Stock Performance

Shares of GNOM stock opened at $45.70 on Friday. Global X Genomics & Biotechnology ETF has a fifty-two week low of $27.20 and a fifty-two week high of $51.42. The firm has a market capitalization of $49.81 million, a price-to-earnings ratio of -19.53 and a beta of 1.22. The stock’s 50-day simple moving average is $47.26 and its 200-day simple moving average is $42.67.

Global X Genomics & Biotechnology ETF Announces Dividend

The business also recently announced a dividend, which was paid on Wednesday, January 7th. Shareholders of record on Tuesday, December 30th were given a dividend of $0.5912 per share. This represents a yield of 259.0%. The ex-dividend date of this dividend was Tuesday, December 30th. Global X Genomics & Biotechnology ETF’s payout ratio is currently -26.50%.

Global X Genomics & Biotechnology ETF Profile

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center.